Compare TOMZ & QNME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOMZ | QNME |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Integrated Freight & Logistics |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 14.1M |
| IPO Year | 2009 | 2024 |
| Metric | TOMZ | QNME |
|---|---|---|
| Price | $1.91 | $0.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.2K | ★ 4.3M |
| Earning Date | 11-13-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.64 | ★ 47.83 |
| EPS | ★ N/A | N/A |
| Revenue | $5,635,927.00 | ★ $5,850,681.00 |
| Revenue This Year | $111.80 | N/A |
| Revenue Next Year | $52.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 111.79 |
| 52 Week Low | $1.21 | $0.26 |
| 52 Week High | $9.73 | $1.40 |
| Indicator | TOMZ | QNME |
|---|---|---|
| Relative Strength Index (RSI) | 68.25 | 44.31 |
| Support Level | $1.28 | $0.29 |
| Resistance Level | $1.95 | $0.94 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 80.24 | 19.68 |
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.